ADITXT INC.

NASDAQ: ADTX (Aditxt, Inc.)

Kemas kini terakhir: 06 Aug, 8:56AM

0.889

-0.01 (-1.07%)

  • 1H -1.07%
  • 5H -25.31%
  • 1B -28.32%
  • 6B -95.91%
  • Tahun Ke Tarikh -98.18%
  • 1T -99.99%
  • 5T -100.00%
Penutupan Terdahulu 0.898
Buka 0.890
Jumlah Dagangan 28,866
Purata Dagangan (3B) 797,322
Modal Pasaran 2,160,806
Harga / Jualan (P/S) 22.27
Harga / Buku (P/B) 0.150
Julat 52 Minggu
0.810 (-8%) — 21,400.00 (2407640%)
Tarikh Pendapatan 18 Aug 2025 - 22 Aug 2025
Margin Operasi (TTM) -550,895.36%
EPS Cair (TTM) -25.94
Pertumbuhan Hasil Suku Tahunan (YOY) -98.70%
Jumlah Hutang/Ekuiti (D/E MRQ) 25.84%
Nisbah Semasa (MRQ) 0.080
Aliran Tunai Operasi (OCF TTM) -22.51 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -17.96 M
Pulangan Atas Aset (ROA TTM) -46.32%
Pulangan Atas Ekuiti (ROE TTM) -204.37%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menurun
Biotechnology (Global) Bercampur Menurun
Stok Aditxt, Inc. Bercampur Bercampur

AISkor Stockmoo

0.0
Konsensus Penganalisis NA
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal -0.5
Purata 0.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ADTX 2 M - - 0.150
MRNA 10 B - - 1.16
CVAC 1 B - 5.45 1.80
ORIC 938 M - - 2.90
SANA 845 M - - 7.11
TSHA 783 M - - 3.22

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Institusi 1.96%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
21 Aug 2025 Pengumuman Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law
19 Aug 2025 Pengumuman FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis
11 Aug 2025 Pengumuman Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative
05 Aug 2025 Pengumuman Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference
29 Jul 2025 Pengumuman Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases
24 Jul 2025 Pengumuman Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test
15 Jul 2025 Pengumuman Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy
07 Jul 2025 Pengumuman Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization
09 Jun 2025 Pengumuman Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors
05 Jun 2025 Pengumuman Saundra Pelletier, Evofem Biosciences’ CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6
1.331.331.151.150.9670.9670.7860.7860.6040.604Aug 6Aug 6Aug 7Aug 7Aug 8Aug 8Aug 11Aug 11Aug 12Aug 12Aug 13Aug 13Aug 14Aug 14Aug 15Aug 15

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0000.000-0.020-0.020-0.040-0.040-0.060-0.060-0.080-0.080MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda